Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8419113 | 0.81 | SRD5A2 (0.45) | SMN1; SMN2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL557185 | 0.78 | CA2 (0.46) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL16069970 | 0.77 | NR4A1 (0.58) | SMN1; SMN2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL16069969 | 0.77 | NR4A1 (0.58) | SMN1; SMN2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL16069992 | 0.77 | NR4A1 (0.58) | SMN1; SMN2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL5795784 | 0.74 | PTPN1 (0.48) | SMN1; SMN2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL5893048 | 0.73 | RXRA (0.46) | ALDH1A1TSHRPTPN1LMNAHPGD | |
| SCHEMBL556251 | 0.73 | NR4A1 (0.41) | SMN1; SMN2ALDH1A1TSHRMAPTMEN1 | |
| SCHEMBL556252 | 0.73 | PDPK1 (0.40) | SMN1; SMN2ALDH1A1TSHRMAPTMEN1 | |
| SCHEMBL24984756 | 0.72 | MAPT (0.41) | ALDH1A1TSHRMAPTKMT2APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | STAT3, JAK2, STAT6 | SMN1; SMN2 4774/4885ALDH1A1 3790/4885TSHR 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.